Gaurav Munj 2022-03-04T06:42:16+00:00 CREATING SHAREHOLDER VALUE Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy View All Press Releases View All Events May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy View All Press Releases View All Events May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy